Diclofenac Sodium/Orphenadrine Citrate

双氯芬酸钠/枸橼酸奥芬那君

Report date: 2022/04/15 13:51:47

Base Information

Drug NameDiclofenac Sodium/Orphenadrine Citrate
Drug Alias NameDiclofenac Sodium+Orphenadrine Citrate双氯芬酸钠和枸橼酸奥芬那君Diclofenac Sodium-Orphenadrine Citrate双氯芬酸钠•枸橼酸奥芬那君双氯芬酸钠-枸橼酸奥芬那君 +[11] 
ClassificationSmall molecules
Mechanisms of ActionHistamine H1 receptor antagonistsGlutamate [NMDA] receptor antagonistsCyclooxygenases inhibitors
TargetsHistamine H1 receptorGlutamate [NMDA] receptorCyclooxygenases
Therapy Area/IndicationsPain, Postoperative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Diclofenac SodiumOrphenadrine Citrate
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFresenius Kabi Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFresenius Kabi Ag
Active IndicationsN/A
Inactive IndicationsPain, Postoperative

Other Information

ATC CodeN/A
Related LinksN/A